Investigational Triple-Action Drug Retatrutide Cuts Blood Sugar and Triggers Major Weight Loss in Type 2 Diabetes Trial
In a phase-3 study, the once-weekly injection retatrutide lowered HbA1c by up to 1.9% and reduced body weight by up to 15% in adults with type-2 diabetes not on other medications.
A phase-3 trial (TRANSCEND-T2D-1) published in The Lancet found that retatrutide, an investigational weekly injection, markedly improved glycaemic control and produced significant weight loss in adults with type-2 diabetes who were not taking other diabetes drugs. After 40 weeks, participants receiving retatrutide saw average HbA1c reductions of 1.7% to 1.9%, compared with a 0.8% drop in the placebo group. Body-weight loss averaged 11.5% to 15.3% on the drug, versus 2.6% with placebo.
Retatrutide belongs to a new class of GLP-3 agonists that simultaneously activate three metabolic receptors—GIP, GLP-1 and glucagon. By engaging the glucagon pathway in addition to the more common GLP-1 and GIP targets, the compound aims to lower blood sugar, curb appetite and boost energy expenditure, potentially delivering greater weight reduction than existing therapies.
The most frequent adverse events were mild to moderate gastrointestinal symptoms such as nausea and diarrhea, which tended to lessen over time. Researchers noted that the triple-action profile could benefit patients requiring more intensive treatment, but emphasized that further trials and longer-term follow-up are needed to confirm safety and efficacy.